UBS Group Has Lowered Expectations for Moderna (NASDAQ:MRNA) Stock Price

Moderna (NASDAQ:MRNA) had its target price cut by UBS Group from $108.00 to $96.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also recently issued reports on MRNA. Argus cut Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Berenberg Bank began coverage on shares of Moderna in a research report on Tuesday, November 19th. They issued a “hold” rating and a $42.00 price objective on the stock. Barclays dropped their price target on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. The Goldman Sachs Group dropped their price target on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research note on Monday, September 16th. Finally, Jefferies Financial Group reduced their price objective on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research note on Tuesday, October 15th. Four equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus target price of $78.83.

Moderna Trading Down 2.1 %

NASDAQ:MRNA opened at $42.25 on Wednesday. The firm has a market cap of $16.26 billion, a P/E ratio of -7.26 and a beta of 1.60. The firm has a 50-day simple moving average of $42.52 and a 200-day simple moving average of $69.84. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. Moderna has a one year low of $35.80 and a one year high of $170.47.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.39) earnings per share. Equities analysts anticipate that Moderna will post -9.3 EPS for the current fiscal year.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders have sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Moderna

A number of institutional investors have recently added to or reduced their stakes in the business. Ashton Thomas Private Wealth LLC bought a new position in shares of Moderna in the second quarter valued at $26,000. Plato Investment Management Ltd grew its position in shares of Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after acquiring an additional 288 shares during the period. Blue Trust Inc. raised its stake in shares of Moderna by 365.6% in the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after buying an additional 574 shares during the period. Larson Financial Group LLC lifted its holdings in Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after purchasing an additional 317 shares during the last quarter. Finally, Rakuten Securities Inc. boosted its holdings in Moderna by 477.3% in the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock worth $63,000 after buying an additional 778 shares during the period. 75.33% of the stock is owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.